OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
30 août 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
Clinical Chemistry Analyzers Market Size to Worth USD 24.8 BN by 2032
18 août 2023 10h45 HE
|
Precedence Research
Ottawa, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The global clinical chemistry analyzers market size was valued at USD 14.63 billion in 2022. The advancement of the technologies behind clinical chemistry...
Disposable Endoscopes Market to hit USD 9.7 billion by 2032, says Global Market Insights Inc.
13 août 2023 21h30 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Aug. 13, 2023 (GLOBE NEWSWIRE) -- Disposable Endoscopes Market size is expected to reach USD 9.7 billion by 2032. The industry is driven by technological advancements in the...
[Latest] Global Patient Simulator Market Size/Share Worth USD 1,421.5 Million by 2032 at a 8.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
01 août 2023 12h30 HE
|
Custom Market Insights
Austin, TX, USA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Patient Simulator Market Size, Trends and Insights By Product Type (Adult...
New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions
28 juil. 2023 09h30 HE
|
HeartFlow Holding, Inc.
MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of...
OKYO Pharma Plans to Initiate Phase 2 Trial of OK-101 in Neuropathic Corneal Pain (“NCP”) Following Announcement of Clinical Trial Agreement with Tufts Medical Center
28 juil. 2023 07h01 HE
|
OKYO Pharma LTD
OKYO plans a 40-patient OK-101 open-label clinical trial with Dr Pedram Hamrah, Tufts Medical Center, as Principal Investigator, a leading expert in treating patients with NCPSecond clinical...
AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer
11 juil. 2023 07h00 HE
|
AccuStem Sciences, Inc
StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrence LONDON and PHOENIX, July 11, 2023 (GLOBE NEWSWIRE)...
PharmAla Biotech Receives Export Permit to Ship GMP LaNeo MDMA to the University of Sydney
16 juin 2023 09h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, June 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF, a biotechnology company focused on the research,...
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
09 juin 2023 15h48 HE
|
PharmAla Biotech
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA VANCOUVER, British Columbia, June 09, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE:...
OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer
02 juin 2023 03h11 HE
|
OBI Pharma Inc.
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth...